aXichem (AXIC) Q4 2025 earnings summary

Executive summary

• Achieved record net sales of SEK 18,446 thousand for 2025, up from SEK 8,570 thousand year-over-year.

• Operating loss widened to SEK -17,491 thousand from SEK -15,827 thousand year-over-year.

• Significant commercial progress with product launches and regulatory milestones in Brazil and the EU.

• Strong development of aXiviteⓇ in the sports nutrition market and aXiphenⓇ in animal feed.

Financial highlights

• Net sales increased 115% year-over-year to SEK 18,446 thousand.

• Operating profit for the year was SEK -17,491 thousand; profit after tax SEK -17,636 thousand.

• Cash and cash equivalents at year-end were SEK 3,084 thousand, down from SEK 14,359 thousand.

• Equity ratio at year-end was 87%, compared to 94% the previous year.

• Earnings per share improved to SEK -0.30 from SEK -0.46 year-over-year.

Outlook and guidance

• Expects continued sales growth in both animal feed and dietary supplements segments.

• Ongoing regulatory processes in the EU and Brazil expected to drive future sales.

• Anticipates increased order intake and market expansion in 2026.